A new way of taking Tysabri (natalizumab) has been approved for the UK and Ireland.
The MHRA (Medicines and Healthcare products Regulatory Agency) and European Commission have granted marketing authorisation for an under-the-skin (subcutaneous) injection of Tysabri.
At the moment, it takes several hours to have a Tysabri infusion in a hospital clinic and some people have to travel a long distance to get to their infusion clinic.
Subcutaneous injections will take less time than the infusion and could be given in a clinic closer to home, such as at a local hospital or health centre. Monthly subcutaneous Tysabri will be given by a health professional.
Clinical trials have shown that monthly subcutaneous injections of Tysabri are as effective as monthly infusions at reducing relapses and lesions seen on MRI scans. About 7% of people (less than 1 in 10) experienced mild or moderate injection site reactions when having a subcutaneous injection of Tysabri.
More about Tysabri
Tysabri is a disease modifying drug for very active relapsing remitting MS (two or more relapses in one year, with signs of increasing or new lesions between two consecutive MRI scans). It reduces the number of relapses by about two thirds (70%), compared to taking placebo.
Common side effects include dizziness, nausea, urticaria (a skin rash) and shivering. Treatment with Tysabri may increase the risk of progressive multifocal leukoencephalopathy (PML), an uncommon brain infection.
New study provides strong evidence for role of Epstein Barr virus as a trigger for multiple sclerosis
14 Jan 2022 - 00:00
New research has provided evidence that infection with the Epstein Barr virus acts as a trigger for people to develop MS.
The PANORAMIC trial for Covid-19 treatment
23 Dec 2021 - 00:00
If you are not eligible to receive Covid-19 treatment automatically on the basis of increased risk, you may be able to get antiviral medication through the PANORAMIC clinical trial.
Ponvory (ponesimod) approved for relapsing remitting MS in England and Wales
23 Dec 2021 - 00:00
The MS Trust is delighted that Ponvory (ponesimod) has been approved in England and Wales for people with active relapsing remitting multiple sclerosis.
Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.